Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia | Aplastic Anemia and MDS International Foundation

Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia

Journal Title: 
Leuk Res Rep
Author(s): 
Jain P, Klotz J, Dunavin N, Lu K, Koklanaris E, Draper D, Superata J, Chinian F, Yu Q, Keyvanfar K, Wong S, Muranski P, Barrett AJ, Ito S, Battiwalla M
Primary Author: 
Jain P
Original Publication Date: 
Thursday, April 13, 2017

Patients with high risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) are commonly older with multiple co-morbidities, rendering them unsuitable for intensive induction chemotherapy or transplantation. We report preliminary cellular immune profiling of four cases receiving sequential clofarabine and lenalidomide for high risk MDS and AML in a phase I study. Our results highlight the potential of immune profiling for monitoring immune-modifying agents in high risk MDS and AML.